Ambros Therapeutics Launches with $125M to Advance Non-Opioid Pain Drug Neridronate for Rare Disease CRPS-1
核心洞察
Ambros Therapeutics (搜索) launched with $125 million Series A financing to advance neridronate, a non-opioid bisphosphonate (搜索) therapy, through Phase 3 trials for Complex Regional Pain Syndrome Type 1 (搜索) (CRPS-1 (搜索)).
The FDA has granted neridronate breakthrough therapy, fast track, and orphan drug designations for CRPS-1 (搜索), a rare debilitating condition affecting an estimated 65,000 new patients annually in the United States.
Neridronate is already approved in Italy based on two Phase 3 studies and has been used in over 600,000 patients, but no FDA-approved medicines currently exist for CRPS-1 (搜索) outside of Italy.
Ambros Therapeutics (搜索) launched as a clinical-stage biotechnology company with $125 million in Series A financing to advance neridronate, a non-opioid bisphosphonate (搜索) therapy, through Phase 3 registrational trials for Complex Regional Pain Syndrome Type 1 (搜索) (CRPS-1 (搜索)). The oversubscribed financing round was co-led by RA Capital Management (搜索) and Patient Square Capital (搜索)'s platform Enavate Sciences (搜索), with participation from Abiogen Pharma (搜索), Janus Henderson Investors, Arkin Bio, Balyasny Asset Management, Transhuman Capital, Adage Capital Partners LP, and other dedicated life sciences investors.
FDA Designations Support Accelerated Development Path
The U.S. Food and Drug Administration has granted neridronate breakthrough therapy, fast track, and orphan drug designations for the treatment of CRPS. These regulatory designations are expected to facilitate expedited development and review processes for the therapy, which targets a rare disease with significant unmet medical need.
CRPS-1 (搜索) is a severe, debilitating rare disease with an estimated 65,000 new cases annually in the United States. The condition is characterized by intense, continuous pain in the affected limb, typically in extremities such as the arm, leg, hand or foot. Patients experience an evolving condition that begins with a "warm" phase lasting approximately six to twelve months after initial injury, where inflammation causes the affected limb to become red, swollen, warm, and painful, progressing to a chronic "cold" phase with ongoing, debilitating pain.
Proven Track Record in Italian Market
Ambros licensed the rights to neridronate from Italian pharmaceutical company Abiogen Pharma (搜索) S.p.A. under a strategic collaboration, providing exclusive rights to neridronate in North America with an option for broader market expansion. Neridronate was approved in Italy based on safety and efficacy demonstrated in two CRPS Phase 3 studies and has been used for CRPS and other disorders in more than 600,000 patients to date.
"We are launching Ambros with a seasoned leadership team and a therapy that has been used to treat CRPS in Italy for over ten years," said Jay Hagan, Chief Executive Officer of Ambros Therapeutics (搜索). "With no approved medicines for CRPS-1 (搜索) outside of Italy, we look forward to working with Abiogen Pharma (搜索) to advance neridronate through Phase 3 and bring this therapy to patients who urgently need it."
Novel Bisphosphonate Mechanism
Neridronate is a novel bisphosphonate (搜索) that was discovered, developed, and commercialized by Abiogen Pharma (搜索) S.p.A. for the Italian market. The drug belongs to a class targeting bisphosphonate, which is believed to have a role in preventing soft tissue calcification and in regulating bone mineralization. Clinical studies have demonstrated lasting pain reduction along with improvements in other CRPS-related symptoms.
Beyond CRPS, neridronate is approved in Italy for additional indications including osteogenesis imperfecta (搜索) and Paget's disease (搜索). Its well-established safety profile and therapeutic benefits position it as a potential promising treatment for patients with CRPS-1 (搜索) worldwide.
Phase 3 Trial Timeline and Leadership
The financing is expected to support the neridronate pivotal Phase 3 clinical trial in CRPS-1 (搜索) (CRPS-RISE) and related regulatory preparations and pre-commercial activities. The pivotal Phase 3 trial is planned to start enrollment in the first quarter of 2026 and represents a potential first-in-class approach to addressing a disease with no FDA-approved medicines.
Ambros' leadership team includes Jay Hagan as Chief Executive Officer, Gail Cawkwell, M.D., Ph.D., as Chief Medical Officer, Michael Cruse as Chief Operating Officer, Kunal Kishnani as Senior Vice President Corporate Development, and Jennifer Lam as Senior Vice President Finance and Administration. The Board of Directors is chaired by industry veteran Keith Katkin and includes Co-Founder Vivek Ramaswamy, Matthew Hammond, Ph.D., of RA Capital Management (搜索), Trit Garg, M.D., of Patient Square Capital (搜索), Prisca Di Martino of Abiogen Pharma (搜索), and Jay Hagan.
"Neridronate is one of the few late-stage programs with a well-established mechanism, extensive real-world experience, and the potential to meaningfully change the trajectory of CRPS-1 (搜索)," said Matthew Hammond, Partner at RA Capital Management (搜索). "We are pleased to support Ambros as it advances this important therapy through this pivotal program to potentially be available for patients with very few options to address this painful disease."